APCC 2017 Interviews - Jonathan Epstien
Jonathan Epstein discusses the critical role of pathological grading in determining men suitable active surveillance.
17 Marras 20172min
APCC 2017 Interviews - Peter Black
Peter Black discusses lessons learned from immunotherapy in bladder cancer and what we might need to look out for in prostate cancer.
17 Marras 20172min
APCC 2017 Interviews - Chris Sweeney 2
Chris Sweeney discusses which is best? Abiraterone vs docetaxal with ADT for hormone naïve metastatic prostate cancer
17 Marras 20171min
APCC 2017 Interviews - Chris Sweeney
Chris Sweeney discusses upfront combination therapy and immunotherapy in men with metastatic prostate cancer
17 Marras 20173min
APCC 2017 Interviews - Piet Ost
Piet Ost discusses the STOMP trial and the benefits of metastasis directed therapy in oligometastatic disease
16 Marras 20173min
APCC 2017 Interviews - John Oliffe
John Oliffe discusses the factors contributing to depression and suicidality in men with prostate cancer
16 Marras 20172min
USANZ 2017 Interview - A/Prof Nathan Lawrentschuk
A/Prof Nathan Lawrentschuk, USANZ 2017 convener, host of Talking Urology & Urological Surgeon & Urologic Oncologist. Joseph discusses with Nathan highlights of USANZ 2017 and the emerging themes. Ta...
29 Elo 20172min
USANZ 2017 Interview - A/Prof Shankar Siva
A/Prof Shankar Siva, Radiation Oncologist & NHMRC fellow at the Peter MacCallum Cancer Centre, Melbourne. Shankar argues the case for metastasis directed therapy with Joseph in oligometastatic diseas...
29 Elo 20175min
